[
  {
    "title": "恒瑞医药(600276.SH)：ω-3鱼油中长链脂肪乳/氨基酸(16)/葡萄糖(30%)注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2023/01/06162737264344.shtml",
    "datetime": "2023-01-06 16:27:38",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2023/01/06162637264334.shtml",
    "datetime": "2023-01-06 16:26:37",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：截至12月底已累计回购1200.0031万股",
    "href": "http://stock.jrj.com.cn/2023/01/04160537258442.shtml",
    "datetime": "2023-01-04 16:05:38",
    "code": "600276"
  },
  {
    "title": "国泰君安证券1月金股：东方雨虹、迎驾贡酒、恒瑞医药、国金证券等",
    "href": "http://stock.jrj.com.cn/hotstock/2023/01/03115337254624.shtml",
    "datetime": "2023-01-03 11:53:14",
    "code": "600276"
  },
  {
    "title": "“金智奖”2022金融界上市公司价值评选结果揭晓 恒瑞医药等10家公司荣获中国医药生物产业优秀商业实践奖",
    "href": "http://stock.jrj.com.cn/2022/12/30161237249740.shtml",
    "datetime": "2022-12-30 16:12:59",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：获得注射用甲苯磺酸瑞马唑仑的药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/12/23155337234248.shtml",
    "datetime": "2022-12-23 15:53:29",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：获得注射用甲苯磺酸瑞马唑仑药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/12/23155237234228.shtml",
    "datetime": "2022-12-23 15:52:52",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：布比卡因脂质体注射液获药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/12/08155037198283.shtml",
    "datetime": "2022-12-08 15:50:24",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：布比卡因脂质体注射液获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/12/08153837198192.shtml",
    "datetime": "2022-12-08 15:38:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：公司副总经理张晓静辞职",
    "href": "http://stock.jrj.com.cn/2022/12/04160137186874.shtml",
    "datetime": "2022-12-04 16:01:02",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：副总经理、首席医学执行官(肿瘤)张晓静辞职",
    "href": "http://stock.jrj.com.cn/2022/12/04154737186855.shtml",
    "datetime": "2022-12-04 15:47:27",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：截至11月底已累计回购约1200万股",
    "href": "http://stock.jrj.com.cn/2022/12/02155337184504.shtml",
    "datetime": "2022-12-02 15:53:40",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：子公司获得HR20031片药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/11/28153637170896.shtml",
    "datetime": "2022-11-28 15:36:20",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR20031片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/11/28153537170908.shtml",
    "datetime": "2022-11-28 15:35:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：钆布醇注射液获得美国FDA批准文号",
    "href": "http://stock.jrj.com.cn/2022/11/21162537154338.shtml",
    "datetime": "2022-11-21 16:25:55",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：钆布醇注射液获得美国FDA批准文号",
    "href": "http://stock.jrj.com.cn/2022/11/21162537154326.shtml",
    "datetime": "2022-11-21 16:25:43",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片拟纳入优先审评程序",
    "href": "http://stock.jrj.com.cn/2022/11/17153637146592.shtml",
    "datetime": "2022-11-17 15:36:54",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：子公司获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/11/16155737143615.shtml",
    "datetime": "2022-11-16 15:57:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-1780片获批开展用于慢性肾脏病的临床试验",
    "href": "http://stock.jrj.com.cn/2022/11/16154537143601.shtml",
    "datetime": "2022-11-16 15:45:15",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-1358片获批开展用于治疗晚期恶性实体瘤的临床试验",
    "href": "http://stock.jrj.com.cn/2022/11/16154337143604.shtml",
    "datetime": "2022-11-16 15:43:25",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-7367注射液获批开展用于治疗晚期恶性实体瘤的临床试验",
    "href": "http://stock.jrj.com.cn/2022/11/16154137143606.shtml",
    "datetime": "2022-11-16 15:41:42",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：艾玛昔替尼片在改善皮肤瘙痒方面的疗效显著优于安慰剂",
    "href": "http://stock.jrj.com.cn/2022/11/15154337140275.shtml",
    "datetime": "2022-11-15 15:43:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：2022年员工持股计划非交易过户完成",
    "href": "http://stock.jrj.com.cn/2022/11/07173437117600.shtml",
    "datetime": "2022-11-07 17:34:04",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片被药审中心拟纳入突破性治疗品种公示名单",
    "href": "http://stock.jrj.com.cn/2022/11/06180337115358.shtml",
    "datetime": "2022-11-06 18:03:43",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：截至10月底已累计耗资3.98亿元回购1200万股",
    "href": "http://stock.jrj.com.cn/2022/11/02154637106521.shtml",
    "datetime": "2022-11-02 15:46:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)第三季度净利润10.54亿元、同比下降31.54%",
    "href": "http://stock.jrj.com.cn/2022/10/30004137096915.shtml",
    "datetime": "2022-10-30 00:41:14",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：相关药品拟纳入突破性治疗品种公示",
    "href": "http://stock.jrj.com.cn/2022/10/23163737075731.shtml",
    "datetime": "2022-10-23 16:37:44",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司SHR-A1811注射液、SHR-1701注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/10/21164637073577.shtml",
    "datetime": "2022-10-21 16:46:21",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：羟乙磺酸达尔西利片的药品上市许可申请获国家药监局受理",
    "href": "http://stock.jrj.com.cn/2022/10/20164537070294.shtml",
    "datetime": "2022-10-20 16:45:22",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：成都盛迪通过药品GMP符合性检查",
    "href": "http://stock.jrj.com.cn/2022/10/17174937061027.shtml",
    "datetime": "2022-10-17 17:49:36",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：截至9月底累计回购1200.0万股",
    "href": "http://stock.jrj.com.cn/2022/10/10203737045146.shtml",
    "datetime": "2022-10-10 20:37:43",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片的药品上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/10/10203637045147.shtml",
    "datetime": "2022-10-10 20:36:21",
    "code": "600276"
  },
  {
    "title": "反攻号角吹响！医药股全线爆发，恒瑞医药涨超6%",
    "href": "http://stock.jrj.com.cn/2022/09/29100737030011.shtml",
    "datetime": "2022-09-29 10:07:58",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：子公司药品盐酸右美托咪定鼻喷雾剂拟纳入优先审评程序",
    "href": "http://stock.jrj.com.cn/2022/09/26165337021874.shtml",
    "datetime": "2022-09-26 16:53:07",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：子公司拟增资扩股引入恒瑞集团等新股东",
    "href": "http://stock.jrj.com.cn/2022/09/23172737017577.shtml",
    "datetime": "2022-09-23 17:27:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：子公司拟增资扩股引入恒瑞集团等新股东",
    "href": "http://stock.jrj.com.cn/2022/09/23171337017522.shtml",
    "datetime": "2022-09-23 17:13:58",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：瑞宏迪拟增资扩股引入新股东 公司将不再持有其控股权",
    "href": "http://stock.jrj.com.cn/2022/09/23165537017480.shtml",
    "datetime": "2022-09-23 16:55:43",
    "code": "600276"
  },
  {
    "title": "2000亿“药茅”前董事长内幕交易获利45万，丢掉千万年薪职位",
    "href": "http://stock.jrj.com.cn/2022/09/21084037009988.shtml",
    "datetime": "2022-09-21 08:40:50",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：子公司获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/09/19172937005216.shtml",
    "datetime": "2022-09-19 17:29:21",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-A2102注射液获批开展用于治疗晚期实体瘤的临床试验",
    "href": "http://stock.jrj.com.cn/2022/09/19172737005237.shtml",
    "datetime": "2022-09-19 17:27:08",
    "code": "600276"
  },
  {
    "title": "恒瑞医药推1.3折员工持股迎创新挑战 孙飘扬复出转型承压净利近18年首降",
    "href": "http://stock.jrj.com.cn/2022/09/15105236996435.shtml",
    "datetime": "2022-09-15 10:52:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-6209胶囊获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/09/14165636994374.shtml",
    "datetime": "2022-09-14 16:56:06",
    "code": "600276"
  },
  {
    "title": "东吴证券点评恒瑞医药：集采负面影响缓解，创新逐渐兑现，迎接业绩拐点",
    "href": "http://stock.jrj.com.cn/hotstock/2022/09/14081236992972.shtml",
    "datetime": "2022-09-14 08:12:57",
    "code": "600276"
  },
  {
    "title": "孙飘扬重掌帅印一年有余，昔日“药茅”恒瑞医药路在何方？",
    "href": "http://stock.jrj.com.cn/2022/09/13080136989930.shtml",
    "datetime": "2022-09-13 08:01:55",
    "code": "600276"
  },
  {
    "title": "宗庆后、钟睒睒，首富都爱私募股权！千亿“药茅”恒瑞医药也在加码",
    "href": "http://stock.jrj.com.cn/2022/09/11113636988474.shtml",
    "datetime": "2022-09-11 11:36:45",
    "code": "600276"
  },
  {
    "title": "千亿“药茅”恒瑞医药也在加码私募股权？",
    "href": "http://stock.jrj.com.cn/2022/09/11104336988462.shtml",
    "datetime": "2022-09-11 10:43:15",
    "code": "600276"
  },
  {
    "title": "恒瑞医药员工可“骨折价”买股票",
    "href": "http://stock.jrj.com.cn/2022/09/09163736986613.shtml",
    "datetime": "2022-09-09 16:37:45",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：员工持股计划拟受让回购股份价格约4.41元",
    "href": "http://stock.jrj.com.cn/2022/09/08172636983679.shtml",
    "datetime": "2022-09-08 17:26:20",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)截至8月底已累计回购111.69万股",
    "href": "http://stock.jrj.com.cn/2022/09/02164136968299.shtml",
    "datetime": "2022-09-02 16:41:23",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRG2101吸入剂获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/09/01170836963349.shtml",
    "datetime": "2022-09-01 17:08:51",
    "code": "600276"
  },
  {
    "title": "恒瑞医药中报点评：“疫情+集采”反应充分，期待边际向好",
    "href": "http://stock.jrj.com.cn/hotstock/2022/08/25080136933805.shtml",
    "datetime": "2022-08-25 08:01:51",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-9821吸入混悬液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/08/23170736926593.shtml",
    "datetime": "2022-08-23 17:07:47",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：2022年上半年营收、净利润同比双降",
    "href": "http://stock.jrj.com.cn/2022/08/22095836920245.shtml",
    "datetime": "2022-08-22 09:58:08",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：集采降价致业绩短期承压，销售改革成效显著，股权激励强化信心",
    "href": "http://stock.jrj.com.cn/hotstock/2022/08/22083136919930.shtml",
    "datetime": "2022-08-22 08:31:58",
    "code": "600276"
  },
  {
    "title": "断崖式下跌！“医药茅”部分集采品种收入大降88%",
    "href": "http://stock.jrj.com.cn/2022/08/22072136919740.shtml",
    "datetime": "2022-08-22 07:21:24",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：上半年净利润21.19亿元 同比下降20.55%",
    "href": "http://stock.jrj.com.cn/2022/08/19171736916635.shtml",
    "datetime": "2022-08-19 17:17:21",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：拟使用不超60亿元闲置自有资金进行委托理财",
    "href": "http://stock.jrj.com.cn/2022/08/19171636916652.shtml",
    "datetime": "2022-08-19 17:16:57",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-5965片获批临床",
    "href": "http://stock.jrj.com.cn/2022/08/15162936900372.shtml",
    "datetime": "2022-08-15 16:29:29",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：HR20014注射液获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/08/09160036882854.shtml",
    "datetime": "2022-08-09 16:00:26",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR20014注射液获批开展糖尿病适应症临床试验",
    "href": "http://stock.jrj.com.cn/2022/08/09155736882844.shtml",
    "datetime": "2022-08-09 15:57:31",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-4642注射液获批开展晚期实体瘤的临床试验",
    "href": "http://stock.jrj.com.cn/2022/08/02162336862974.shtml",
    "datetime": "2022-08-02 16:23:08",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：截至7月底已累计回购108.687万股",
    "href": "http://stock.jrj.com.cn/2022/08/02162236862976.shtml",
    "datetime": "2022-08-02 16:22:53",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用HRS-8427获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/07/29161536853894.shtml",
    "datetime": "2022-07-29 16:15:07",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片、阿得贝利单抗注射液、注射用SHR-A1811获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/07/25171636840372.shtml",
    "datetime": "2022-07-25 17:16:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司阿得贝利单抗注射液、注射用SHR-1802获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/07/25171236840378.shtml",
    "datetime": "2022-07-25 17:12:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)拉升涨5%",
    "href": "http://stock.jrj.com.cn/2022/07/14101336810257.shtml",
    "datetime": "2022-07-14 10:13:11",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1701注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/07/11162836799058.shtml",
    "datetime": "2022-07-11 16:28:42",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-1167片获批开展晚期实体肿瘤的临床试验",
    "href": "http://stock.jrj.com.cn/2022/07/11162636799063.shtml",
    "datetime": "2022-07-11 16:26:59",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR8554注射液的药品上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/07/08164736794791.shtml",
    "datetime": "2022-07-08 16:47:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：截至6月底已累计回购108.687万股",
    "href": "http://stock.jrj.com.cn/2022/07/01170936775624.shtml",
    "datetime": "2022-07-01 17:09:11",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司的他克莫司缓释胶囊获批上市",
    "href": "http://stock.jrj.com.cn/2022/07/01170836775627.shtml",
    "datetime": "2022-07-01 17:08:01",
    "code": "600276"
  },
  {
    "title": "恒瑞医药连续第二日上涨 股价创近4个月新高 瑞维鲁胺片获批上市",
    "href": "http://stock.jrj.com.cn/2022/07/01103936774312.shtml",
    "datetime": "2022-07-01 10:39:05",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：瑞维鲁胺片获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/06/29165836768139.shtml",
    "datetime": "2022-06-29 16:58:33",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：海曲泊帕乙醇胺片获美国FDA孤儿药资格认定",
    "href": "http://stock.jrj.com.cn/2022/06/14182436728490.shtml",
    "datetime": "2022-06-14 18:24:56",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片获药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/06/06170336706026.shtml",
    "datetime": "2022-06-06 17:03:49",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：截至5月底已累计回购108.69万股",
    "href": "http://stock.jrj.com.cn/2022/06/02162036700591.shtml",
    "datetime": "2022-06-02 16:20:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1918注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/05/31180836693893.shtml",
    "datetime": "2022-05-31 18:08:35",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司地夸磷索钠滴眼液获批上市",
    "href": "http://stock.jrj.com.cn/2022/05/30163536689776.shtml",
    "datetime": "2022-05-30 16:35:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：控股公司拟协议转让上海甫弘100%股权",
    "href": "http://stock.jrj.com.cn/2022/05/27181236685410.shtml",
    "datetime": "2022-05-27 18:12:09",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR20033片药品上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/05/27181036685413.shtml",
    "datetime": "2022-05-27 18:10:04",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR19042胶囊获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/05/26164636681338.shtml",
    "datetime": "2022-05-26 16:46:44",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司盐酸氨溴索口服溶液能(100ml:0.3g)获批上市",
    "href": "http://stock.jrj.com.cn/2022/05/25165236677865.shtml",
    "datetime": "2022-05-25 16:52:15",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：碘克沙醇注射液获得美国FDA批准文号",
    "href": "http://stock.jrj.com.cn/2022/05/25165036677866.shtml",
    "datetime": "2022-05-25 16:50:49",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-3680-Ⅲ-HSPC研究双主要终点均已达到",
    "href": "http://stock.jrj.com.cn/2022/05/24171236674559.shtml",
    "datetime": "2022-05-24 17:12:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR19024注射液获批开展晚期实体瘤临床试验",
    "href": "http://stock.jrj.com.cn/2022/05/24170536674513.shtml",
    "datetime": "2022-05-24 17:05:01",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：拟用于神经阻滞术后镇痛的注射用HR18034获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/05/19165936662526.shtml",
    "datetime": "2022-05-19 16:59:08",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRG2005吸入剂获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/05/19165736662533.shtml",
    "datetime": "2022-05-19 16:57:11",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-2010注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/05/18165436659020.shtml",
    "datetime": "2022-05-18 16:54:39",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：阿得贝利单抗注射液、SHR-8068注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/05/17164336655394.shtml",
    "datetime": "2022-05-17 16:43:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：相关SHR-1210-Ⅲ-310研究被判定主要研究终点结果达到方案预设的优效标准",
    "href": "http://stock.jrj.com.cn/2022/05/12173736643350.shtml",
    "datetime": "2022-05-12 17:37:06",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司ω-3脂肪酸乙酯90软胶囊获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/05/10163836621039.shtml",
    "datetime": "2022-05-10 16:38:09",
    "code": "600276"
  },
  {
    "title": "医药大佬孙飘扬复出272天，恒瑞医药没了2100亿",
    "href": "http://stock.jrj.com.cn/2022/04/27225836487415.shtml",
    "datetime": "2022-04-27 22:58:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：盐酸伊立替康脂质体注射液药物临床试验获批",
    "href": "http://stock.jrj.com.cn/2022/04/27223536487046.shtml",
    "datetime": "2022-04-27 22:35:13",
    "code": "600276"
  },
  {
    "title": "恒瑞医药核心产品价格大幅下降 业绩短期承压",
    "href": "http://stock.jrj.com.cn/2022/04/27090436481278.shtml",
    "datetime": "2022-04-27 09:04:26",
    "code": "600276"
  },
  {
    "title": "【聚焦打新】破发率走高，打新基金规模缩水明显",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/27085036481050.shtml",
    "datetime": "2022-04-27 08:50:21",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：仿制药集采致业绩短期承压，创新药营收占比持续提升",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/27084336481024.shtml",
    "datetime": "2022-04-27 08:43:12",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)绩后连续第二日下跌 较最高价已回撤70%",
    "href": "http://stock.jrj.com.cn/2022/04/26094236472872.shtml",
    "datetime": "2022-04-26 09:42:04",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：70万股民期待的“最后一跌”何时到？",
    "href": "http://stock.jrj.com.cn/2022/04/26084836472237.shtml",
    "datetime": "2022-04-26 08:48:45",
    "code": "600276"
  },
  {
    "title": "昔日“药茅”今日“药渣”，恒瑞的“单抗”能否扛得住股价？",
    "href": "http://stock.jrj.com.cn/2022/04/26075036471753.shtml",
    "datetime": "2022-04-26 07:50:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药扣非21年首降遭双重挑战 四分之一营收投入研发已有10款创新药上市",
    "href": "http://stock.jrj.com.cn/2022/04/25113736459747.shtml",
    "datetime": "2022-04-25 11:37:10",
    "code": "600276"
  },
  {
    "title": "恒瑞医药大跌超8% 一季度净利润同比下降17.35%",
    "href": "http://stock.jrj.com.cn/2022/04/25094136457906.shtml",
    "datetime": "2022-04-25 09:41:49",
    "code": "600276"
  },
  {
    "title": "恒瑞医药2021年营收259.06亿元，整年累计研发投入62亿元",
    "href": "http://stock.jrj.com.cn/2022/04/25091636457208.shtml",
    "datetime": "2022-04-25 09:16:01",
    "code": "600276"
  },
  {
    "title": "恒瑞医药2021年净利45.3亿同比下滑28.41% 董事长孙飘扬薪酬192.37万",
    "href": "http://stock.jrj.com.cn/2022/04/24155136447566.shtml",
    "datetime": "2022-04-24 15:51:19",
    "code": "600276"
  },
  {
    "title": "恒瑞医药2022年第一季度净利12.37亿同比下滑17.35% 银行理财产品投资收益减少",
    "href": "http://stock.jrj.com.cn/2022/04/23161236437245.shtml",
    "datetime": "2022-04-23 16:12:45",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：一季度净利润12.37亿元 同比下降17.35%",
    "href": "http://stock.jrj.com.cn/2022/04/22193236430950.shtml",
    "datetime": "2022-04-22 19:32:41",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)2021年度净利降28.41%至45.3亿元 拟10派1.6元",
    "href": "http://stock.jrj.com.cn/2022/04/22193036430981.shtml",
    "datetime": "2022-04-22 19:30:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)一季度净利润12.37亿元 同比下降17.35%",
    "href": "http://stock.jrj.com.cn/2022/04/22192736430922.shtml",
    "datetime": "2022-04-22 19:27:09",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：中长链脂肪乳/氨基酸(16)/葡萄糖(16%)注射液获批上市",
    "href": "http://stock.jrj.com.cn/2022/04/18164536385160.shtml",
    "datetime": "2022-04-18 16:45:41",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：钆特酸葡胺注射液获得美国FDA批准文号",
    "href": "http://stock.jrj.com.cn/2022/04/14163936335306.shtml",
    "datetime": "2022-04-14 16:39:15",
    "code": "600276"
  },
  {
    "title": "一副总辞职，恒瑞医药火速任命两名研发高管，最年轻副总上任",
    "href": "http://stock.jrj.com.cn/2022/04/13090936321310.shtml",
    "datetime": "2022-04-13 09:09:40",
    "code": "600276"
  },
  {
    "title": "恒瑞医药副总经理邹建军辞职 2020年薪酬为210万",
    "href": "http://stock.jrj.com.cn/2022/04/12205136317321.shtml",
    "datetime": "2022-04-12 20:51:50",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司HRX0701片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/04/01165536247606.shtml",
    "datetime": "2022-04-01 16:55:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：钆布醇注射液获批上市",
    "href": "http://stock.jrj.com.cn/2022/03/27165135584863.shtml",
    "datetime": "2022-03-27 16:51:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：子公司获得药物临床试验批准通知书 相关项目已投入研发费用约3260万元",
    "href": "http://stock.jrj.com.cn/2022/03/18184034846504.shtml",
    "datetime": "2022-03-18 18:40:46",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司HRS-7535片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/18164534845452.shtml",
    "datetime": "2022-03-18 16:45:03",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：钆特酸葡胺注射液通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/03/17162234839345.shtml",
    "datetime": "2022-03-17 16:22:55",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司注射用SHR-A1811获批临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/14162934824091.shtml",
    "datetime": "2022-03-14 16:29:22",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司SHR-1701注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/14162734824082.shtml",
    "datetime": "2022-03-14 16:27:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)拟6亿-12亿元回购股份 回购价格上限60.22元/股",
    "href": "http://stock.jrj.com.cn/2022/03/13155134819043.shtml",
    "datetime": "2022-03-13 15:51:47",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片、注射用SHR-A1811、SHR-1316注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/11172734814527.shtml",
    "datetime": "2022-03-11 17:27:07",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1816注射液获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/03/09164734558703.shtml",
    "datetime": "2022-03-09 16:47:09",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司肿瘤新药注射用SHR-1501获批临床",
    "href": "http://stock.jrj.com.cn/2022/03/07163534537836.shtml",
    "datetime": "2022-03-07 16:35:16",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR0302片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/07162934537806.shtml",
    "datetime": "2022-03-07 16:29:25",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-2261片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/03/01163834508298.shtml",
    "datetime": "2022-03-01 16:38:41",
    "code": "600276"
  },
  {
    "title": "管理层坐看股价连续下跌？恒瑞医药：将着力于产品结构优化提升，促进业绩可持续增长",
    "href": "http://stock.jrj.com.cn/2022/02/15150134353572.shtml",
    "datetime": "2022-02-15 15:01:06",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：昂丹司琼口溶膜、对乙酰氨基酚甘露醇注射液获批上市",
    "href": "http://stock.jrj.com.cn/2022/02/11153934323444.shtml",
    "datetime": "2022-02-11 15:39:42",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：阿得贝利单抗注射液上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/01/24171334204926.shtml",
    "datetime": "2022-01-24 17:13:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：尼莫地平口服溶液获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/01/24171034204913.shtml",
    "datetime": "2022-01-24 17:10:43",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR8008胶囊的药品上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2022/01/14161834157849.shtml",
    "datetime": "2022-01-14 16:18:09",
    "code": "600276"
  },
  {
    "title": "北向资金净流出5.85亿 恒瑞医药净卖出7.77亿",
    "href": "http://stock.jrj.com.cn/2022/01/13175334154753.shtml",
    "datetime": "2022-01-13 17:53:39",
    "code": "600276"
  },
  {
    "title": "恒瑞医药午后一度跳水跌超5%",
    "href": "http://stock.jrj.com.cn/2022/01/13143534153680.shtml",
    "datetime": "2022-01-13 14:35:13",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：海曲泊帕乙醇胺片获美国FDA临床试验资格 将于近期开展III期临床试验",
    "href": "http://stock.jrj.com.cn/2022/01/11164134146315.shtml",
    "datetime": "2022-01-11 16:41:14",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：脯氨酸恒格列净片和羟乙磺酸达尔西利片获批上市",
    "href": "http://stock.jrj.com.cn/2022/01/10154834141290.shtml",
    "datetime": "2022-01-10 15:48:31",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司盐酸氨溴索口服溶液获批上市",
    "href": "http://stock.jrj.com.cn/2022/01/10154234141227.shtml",
    "datetime": "2022-01-10 15:42:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：甲磺酸阿帕替尼片、注射用卡瑞利珠单抗获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/01/07154134133469.shtml",
    "datetime": "2022-01-07 15:41:28",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：YY-20394联合MIL62在复发难治B细胞非霍奇金淋巴瘤中的临床试验获批",
    "href": "http://stock.jrj.com.cn/2022/01/06171234129970.shtml",
    "datetime": "2022-01-06 17:12:05",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：脯氨酸恒格列净片、羟乙磺酸达尔西利片获批上市",
    "href": "http://stock.jrj.com.cn/2022/01/03155234109209.shtml",
    "datetime": "2022-01-03 15:52:10",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS-3738片获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/12/27173334071378.shtml",
    "datetime": "2021-12-27 17:33:59",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1314注射液获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/12/24160234057917.shtml",
    "datetime": "2021-12-24 16:02:31",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司HRS5685片获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/12/23170534053157.shtml",
    "datetime": "2021-12-23 17:05:42",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：HRS5685片获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/12/23170134053107.shtml",
    "datetime": "2021-12-23 17:01:02",
    "code": "600276"
  },
  {
    "title": "业绩放缓 研发却丝毫不松懈 恒瑞医药创新药期待“开花结果”",
    "href": "http://stock.jrj.com.cn/2021/12/21090534040469.shtml",
    "datetime": "2021-12-21 09:05:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR1459片获批药物临床试验",
    "href": "http://stock.jrj.com.cn/2021/12/20165834034883.shtml",
    "datetime": "2021-12-20 16:58:10",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用卡瑞利珠单抗获药品注册证书 涉及增加适应症",
    "href": "http://stock.jrj.com.cn/2021/12/13162634008773.shtml",
    "datetime": "2021-12-13 16:26:14",
    "code": "600276"
  },
  {
    "title": "将注销1700万股！恒瑞医药终止股权激励计划",
    "href": "http://stock.jrj.com.cn/2021/12/09125433989567.shtml",
    "datetime": "2021-12-09 12:54:35",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：终止实施2020年度限制性股票激励计划并回购注销相关限制性股票",
    "href": "http://stock.jrj.com.cn/2021/12/08180233985563.shtml",
    "datetime": "2021-12-08 18:02:54",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司注射用HRS8179获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/12/08174033985387.shtml",
    "datetime": "2021-12-08 17:40:54",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司药品盐酸非索非那定片通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/12/07172133980562.shtml",
    "datetime": "2021-12-07 17:21:10",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：多项药品获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/12/06155833973794.shtml",
    "datetime": "2021-12-06 15:58:13",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR8554注射液能够有效治疗腹部手术后中重度疼痛",
    "href": "http://stock.jrj.com.cn/2021/12/06153733973648.shtml",
    "datetime": "2021-12-06 15:37:19",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：法米替尼、卡瑞利珠单抗、SHR-1802用于联合治疗晚期实体肿瘤的临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/12/06153433973640.shtml",
    "datetime": "2021-12-06 15:34:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：海曲泊帕乙醇胺片、格隆溴铵注射液等9个产品纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03161633960266.shtml",
    "datetime": "2021-12-03 16:16:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司SHR-2002注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/12/03161333960255.shtml",
    "datetime": "2021-12-03 16:13:29",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1909注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/11/30172533944765.shtml",
    "datetime": "2021-11-30 17:25:47",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1701注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/11/26171733924082.shtml",
    "datetime": "2021-11-26 17:17:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：引进基石药业抗CTLA-4单克隆抗体CS1002",
    "href": "http://stock.jrj.com.cn/2021/11/22082933901618.shtml",
    "datetime": "2021-11-22 08:29:36",
    "code": "600276"
  },
  {
    "title": "基石药业与恒瑞医药就CS1002(抗CTLA-4单抗)达成大中华地区的战略合作及独占许可协议",
    "href": "http://stock.jrj.com.cn/2021/11/21173933892872.shtml",
    "datetime": "2021-11-21 17:39:55",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：与基石药业达成协议 引进基石药业抗CTLA-4单克隆抗体CS1002",
    "href": "http://stock.jrj.com.cn/2021/11/21171133892830.shtml",
    "datetime": "2021-11-21 17:11:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：聘任刘健俊为公司财务总监",
    "href": "http://stock.jrj.com.cn/2021/11/19175033880916.shtml",
    "datetime": "2021-11-19 17:50:38",
    "code": "600276"
  },
  {
    "title": "恒瑞医药财务总监周宋辞职 2020年薪酬为74.11万",
    "href": "http://stock.jrj.com.cn/2021/11/12221133842921.shtml",
    "datetime": "2021-11-12 22:11:25",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：两项药品获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/11/12213233842734.shtml",
    "datetime": "2021-11-12 21:32:06",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司的他氟前列素滴眼液获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/11/12180333841860.shtml",
    "datetime": "2021-11-12 18:03:04",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：周宋辞任财务总监",
    "href": "http://stock.jrj.com.cn/2021/11/12180133841842.shtml",
    "datetime": "2021-11-12 18:01:25",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用甲苯磺酸瑞马唑仑获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/11/12180033841814.shtml",
    "datetime": "2021-11-12 18:00:02",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司SHR2285片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/11/10170833832124.shtml",
    "datetime": "2021-11-10 17:08:29",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司SHR-1701注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/11/10170733832116.shtml",
    "datetime": "2021-11-10 17:07:00",
    "code": "600276"
  },
  {
    "title": "外资罕见砸盘近120亿，医药股突然大爆发！120万元一针抗癌神药进入医保谈判，恒瑞医药、沃森生物狂飙！",
    "href": "http://stock.jrj.com.cn/2021/11/10162933831890.shtml",
    "datetime": "2021-11-10 16:29:35",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)直线拉升逼近涨停",
    "href": "http://stock.jrj.com.cn/2021/11/10131633831318.shtml",
    "datetime": "2021-11-10 13:16:51",
    "code": "600276"
  },
  {
    "title": "恒瑞医药股价午后直线飙升涨逾8％ 成交额超30亿元",
    "href": "http://stock.jrj.com.cn/2021/11/10131133831308.shtml",
    "datetime": "2021-11-10 13:11:56",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：甲磺酸阿帕替尼片、SHR-1701注射液获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/11/08155733823342.shtml",
    "datetime": "2021-11-08 15:57:35",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：获得关于甲磺酸阿帕替尼片、SHR-1701注射液的《药物临床试验批准通知书》",
    "href": "http://stock.jrj.com.cn/2021/11/08155533823335.shtml",
    "datetime": "2021-11-08 15:55:14",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：青岛有沃投资及其一致行动人的持股比例降至4.999999%",
    "href": "http://stock.jrj.com.cn/2021/11/05181133817624.shtml",
    "datetime": "2021-11-05 18:11:33",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR8008胶囊的相关多中心III期临床研究主要研究终点结果达到方案预设的优效标准",
    "href": "http://stock.jrj.com.cn/2021/11/04160433812905.shtml",
    "datetime": "2021-11-04 16:04:19",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：两项药品获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/10/22154233733095.shtml",
    "datetime": "2021-10-22 15:42:36",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：苹果酸法米替尼胶囊、注射用卡瑞利珠单抗获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/10/22153633733061.shtml",
    "datetime": "2021-10-22 15:36:53",
    "code": "600276"
  },
  {
    "title": "三季度营收净利双降 恒瑞医药遭陆股通减持逾5000万股",
    "href": "http://stock.jrj.com.cn/2021/10/21090133725388.shtml",
    "datetime": "2021-10-21 09:01:17",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR011408注射液获批开展用于治疗成人糖尿病的临床试验",
    "href": "http://stock.jrj.com.cn/2021/10/20161433721907.shtml",
    "datetime": "2021-10-20 16:14:46",
    "code": "600276"
  },
  {
    "title": "Q3业绩落地 恒瑞医药(600276.SH)由跌转升",
    "href": "http://stock.jrj.com.cn/2021/10/20114633720835.shtml",
    "datetime": "2021-10-20 11:46:45",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：第三季度营收69.01亿元 同比下降14.84%",
    "href": "http://stock.jrj.com.cn/2021/10/19174333717219.shtml",
    "datetime": "2021-10-19 17:43:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用SHR-A2009获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/10/18165533711339.shtml",
    "datetime": "2021-10-18 16:55:38",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：环磷酰胺胶囊拟纳入优先审评程序",
    "href": "http://stock.jrj.com.cn/2021/10/14154533690851.shtml",
    "datetime": "2021-10-14 15:45:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS7415片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/10/14154233690844.shtml",
    "datetime": "2021-10-14 15:42:07",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司的SHR0302碱软膏Ⅱ期临床研究所探索的碱软膏剂量均达到方案预设的有效终点指标",
    "href": "http://stock.jrj.com.cn/2021/10/11173533673823.shtml",
    "datetime": "2021-10-11 17:35:57",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司收到SHR-1819注射液的药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/10/11173033673797.shtml",
    "datetime": "2021-10-11 17:30:06",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司收到SHR-1701注射液、贝伐珠单抗注射液的药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/10/11172833673783.shtml",
    "datetime": "2021-10-11 17:28:46",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)大涨近9% 创近2个月新高",
    "href": "http://stock.jrj.com.cn/2021/10/08141333657137.shtml",
    "datetime": "2021-10-08 14:13:33",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：普瑞巴林缓释片获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/09/29163833536761.shtml",
    "datetime": "2021-09-29 16:38:16",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：吸入用七氟烷获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/09/29163633536739.shtml",
    "datetime": "2021-09-29 16:36:11",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用环磷酰胺通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/09/29163333536718.shtml",
    "datetime": "2021-09-29 16:33:46",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：收到氟唑帕利胶囊、贝伐珠单抗注射液的药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/28160733530558.shtml",
    "datetime": "2021-09-28 16:07:14",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：获得盐酸伊立替康脂质体注射液、SHR-1701注射液的药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/28160433530548.shtml",
    "datetime": "2021-09-28 16:04:25",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：两款产品获得药监局补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/27174033524570.shtml",
    "datetime": "2021-09-27 17:40:51",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司收到贝伐珠单抗注射液的药品补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/27164033524186.shtml",
    "datetime": "2021-09-27 16:40:31",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用甲苯磺酸瑞马唑仑获得药品补充申请批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/27163733524174.shtml",
    "datetime": "2021-09-27 16:37:40",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片被纳入拟优先审评品种公示名单",
    "href": "http://stock.jrj.com.cn/2021/09/24162933510309.shtml",
    "datetime": "2021-09-24 16:29:09",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用SHR-A1904治疗晚期实体瘤获美国FDA临床试验资格",
    "href": "http://stock.jrj.com.cn/2021/09/24162533510294.shtml",
    "datetime": "2021-09-24 16:25:25",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：SHR7280片获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/16195233446620.shtml",
    "datetime": "2021-09-16 19:52:06",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：马来酸吡咯替尼片的上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2021/09/16185933446383.shtml",
    "datetime": "2021-09-16 18:59:39",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR7280片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/09/16185633446380.shtml",
    "datetime": "2021-09-16 18:56:16",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：非布司他片(20mg)获批上市",
    "href": "http://stock.jrj.com.cn/2021/09/09164933409973.shtml",
    "datetime": "2021-09-09 16:49:47",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1701注射液、贝伐珠单抗注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/09/06153833392067.shtml",
    "datetime": "2021-09-06 15:38:59",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)与天广实生物达成MIL62商业化及联合用药临床开发合作",
    "href": "http://stock.jrj.com.cn/2021/09/05174433385945.shtml",
    "datetime": "2021-09-05 17:44:55",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：与天广实生物达成MIL62商业化及联合用药临床开发合作",
    "href": "http://stock.jrj.com.cn/2021/09/05170433385897.shtml",
    "datetime": "2021-09-05 17:04:42",
    "code": "600276"
  },
  {
    "title": "恒瑞医药子公司HR20033片获得临床试验批准",
    "href": "http://stock.jrj.com.cn/2021/09/03160633380068.shtml",
    "datetime": "2021-09-03 16:06:44",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司药品HR20033片获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/09/03154233379932.shtml",
    "datetime": "2021-09-03 15:42:04",
    "code": "600276"
  },
  {
    "title": "恒瑞医药获得药品注册证书 研发投入4264万元",
    "href": "http://stock.jrj.com.cn/invest/2021/09/03104233379016.shtml",
    "datetime": "2021-09-03 10:42:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：罂粟乙碘油注射液获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/09/02193033375530.shtml",
    "datetime": "2021-09-02 19:30:19",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：碘佛醇注射液通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/09/02192833375520.shtml",
    "datetime": "2021-09-02 19:28:29",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：用于治疗帕金森病的HRG2010胶囊获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/09/01165933368218.shtml",
    "datetime": "2021-09-01 16:59:02",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司注射用HRS6807获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/08/31153833361347.shtml",
    "datetime": "2021-08-31 15:38:25",
    "code": "600276"
  },
  {
    "title": "东吴证券点评恒瑞医药2021年中报：受集采影响公司业绩承压，创新与国际化转型持续加速",
    "href": "http://stock.jrj.com.cn/hotstock/2021/08/25083533314221.shtml",
    "datetime": "2021-08-25 08:35:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药跌幅再度扩大至6% 市值跌破3000亿",
    "href": "http://stock.jrj.com.cn/2021/08/23095133301001.shtml",
    "datetime": "2021-08-23 09:51:24",
    "code": "600276"
  },
  {
    "title": "恒瑞医药业绩远低预期市值缩水超3000亿 陷创新药仿制药两难单季净利10年首降",
    "href": "http://stock.jrj.com.cn/2021/08/23072333300369.shtml",
    "datetime": "2021-08-23 07:23:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药、诚意药业、信邦制药跌停，医疗ETF（159828）跌超6%",
    "href": "http://stock.jrj.com.cn/2021/08/20150733286963.shtml",
    "datetime": "2021-08-20 15:07:55",
    "code": "600276"
  },
  {
    "title": "3100亿“药茅”跌停！高瓴重返十大股东行列，医药股是走还是留？",
    "href": "http://stock.jrj.com.cn/2021/08/20131333286484.shtml",
    "datetime": "2021-08-20 13:13:35",
    "code": "600276"
  },
  {
    "title": "恒瑞医药2021年半年度净利26.68亿元 同比净利增加0.21%",
    "href": "http://stock.jrj.com.cn/2021/08/20121833286251.shtml",
    "datetime": "2021-08-20 12:18:08",
    "code": "600276"
  },
  {
    "title": "A股异动丨中期业绩不及预期 恒瑞医药(600276.SH)大跌9%",
    "href": "http://stock.jrj.com.cn/2021/08/20093433285218.shtml",
    "datetime": "2021-08-20 09:34:15",
    "code": "600276"
  },
  {
    "title": "恒瑞医药半年业绩出炉，营收133亿，创新药占四成，海外临床屡获进展",
    "href": "http://stock.jrj.com.cn/2021/08/19183533281695.shtml",
    "datetime": "2021-08-19 18:35:05",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：上半年净利增0.21%至26.68亿元",
    "href": "http://stock.jrj.com.cn/2021/08/19172833281156.shtml",
    "datetime": "2021-08-19 17:28:06",
    "code": "600276"
  },
  {
    "title": "恒瑞医药半年报：上半年净利26.68亿元 同比增长0.21%",
    "href": "http://stock.jrj.com.cn/2021/08/19172533281136.shtml",
    "datetime": "2021-08-19 17:25:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS2300片获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/08/16154133260491.shtml",
    "datetime": "2021-08-16 15:41:39",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：长效抗真菌药注射用HRS9432获批临床",
    "href": "http://stock.jrj.com.cn/2021/08/12161333243008.shtml",
    "datetime": "2021-08-12 16:13:55",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用卡瑞利珠单抗联合苹果酸法米替尼胶囊获美国FDA临床试验资格",
    "href": "http://stock.jrj.com.cn/2021/08/09164633225761.shtml",
    "datetime": "2021-08-09 16:46:56",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：术后镇痛药注射用HR18034获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/08/06153733212752.shtml",
    "datetime": "2021-08-06 15:37:22",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR19003贴剂将于近期开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/08/05164133207095.shtml",
    "datetime": "2021-08-05 16:41:44",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：选举孙飘扬为第八届董事会董事长",
    "href": "http://stock.jrj.com.cn/2021/08/04161233201254.shtml",
    "datetime": "2021-08-04 16:12:02",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS2398片获药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/08/04153333201052.shtml",
    "datetime": "2021-08-04 15:33:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：丙泊酚中/长链脂肪乳注射液获批上市",
    "href": "http://stock.jrj.com.cn/2021/07/30155933175490.shtml",
    "datetime": "2021-07-30 15:59:41",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：拟以5000万元投资苏州工业园区薄荷三期创投",
    "href": "http://stock.jrj.com.cn/2021/07/30155733175479.shtml",
    "datetime": "2021-07-30 15:57:38",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：磺达肝癸钠注射液通过一致性评价",
    "href": "http://stock.jrj.com.cn/2021/07/28154333164031.shtml",
    "datetime": "2021-07-28 15:43:47",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：3款注射液获得药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/07/27154233158268.shtml",
    "datetime": "2021-07-27 15:42:05",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司的SHR-1906注射液将于近期开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/07/20165333124708.shtml",
    "datetime": "2021-07-20 16:53:35",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用甲苯磺酸瑞马唑仑、注射用HRS3797获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/07/18163733112493.shtml",
    "datetime": "2021-07-18 16:37:51",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：药品“SHR3680片”临床试验取得进展",
    "href": "http://stock.jrj.com.cn/2021/07/15164933102150.shtml",
    "datetime": "2021-07-15 16:49:39",
    "code": "600276"
  },
  {
    "title": "恒瑞医药暴跌35%，还有救吗？",
    "href": "http://stock.jrj.com.cn/2021/07/13190333090471.shtml",
    "datetime": "2021-07-13 19:03:11",
    "code": "600276"
  },
  {
    "title": "周云曙辞任恒瑞医药董事长、总经理等职务",
    "href": "http://stock.jrj.com.cn/2021/07/09212433071701.shtml",
    "datetime": "2021-07-09 21:24:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：董事长、总经理周云曙辞职 孙飘扬代为履行董事长职责",
    "href": "http://stock.jrj.com.cn/2021/07/09160533069908.shtml",
    "datetime": "2021-07-09 16:05:35",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR6508注射液获药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/07/09160233069898.shtml",
    "datetime": "2021-07-09 16:02:52",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：甲磺酸阿帕替尼治疗胃癌或胃食管交界处癌获批临床",
    "href": "http://stock.jrj.com.cn/2021/07/06165233053409.shtml",
    "datetime": "2021-07-06 16:52:59",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用HR20013将于近期开展临床试验",
    "href": "http://stock.jrj.com.cn/2021/07/06164933053399.shtml",
    "datetime": "2021-07-06 16:49:25",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HR17031注射液治疗2型糖尿病在美获批临床",
    "href": "http://stock.jrj.com.cn/2021/07/01154833027571.shtml",
    "datetime": "2021-07-01 15:48:12",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR-1701注射液两个新适应症获批临床",
    "href": "http://stock.jrj.com.cn/2021/06/30180533022663.shtml",
    "datetime": "2021-06-30 18:05:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR1459片治疗原发性膜性肾病申报临床获批",
    "href": "http://stock.jrj.com.cn/2021/06/30175633022544.shtml",
    "datetime": "2021-06-30 17:56:40",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司的HR19034滴眼液临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/06/29154133015776.shtml",
    "datetime": "2021-06-29 15:41:56",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533087379.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533142470.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533178918.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533191304.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533696467.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533112668.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533131946.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533179336.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533128969.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533146659.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533160570.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533169470.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533191031.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围",
    "href": "http://stock.jrj.com.cn/2021/06/28071533203594.shtml",
    "datetime": "2021-06-28 07:15:18",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR7280片治疗前列腺癌获批临床",
    "href": "http://stock.jrj.com.cn/2021/06/25154032996467.shtml",
    "datetime": "2021-06-25 15:40:57",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用HRS3658临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/06/24162832989955.shtml",
    "datetime": "2021-06-24 16:28:32",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR3680片临床试验补充申请获批",
    "href": "http://stock.jrj.com.cn/2021/06/24162532989950.shtml",
    "datetime": "2021-06-24 16:25:37",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)跌超4% 碘克沙醇注射液意外失标",
    "href": "http://stock.jrj.com.cn/2021/06/24101732987791.shtml",
    "datetime": "2021-06-24 10:17:39",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：氟唑帕利胶囊获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/23223532985545.shtml",
    "datetime": "2021-06-23 22:35:12",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司贝伐珠单抗注射液获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/23223132985530.shtml",
    "datetime": "2021-06-23 22:31:15",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：职工支出增加主要原因为人员增长和员工工资上调",
    "href": "http://stock.jrj.com.cn/2021/06/23143532982704.shtml",
    "datetime": "2021-06-23 14:35:58",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：有关董伟与恒瑞及有沃关系相关信息都已公告",
    "href": "http://stock.jrj.com.cn/2021/06/23135232982491.shtml",
    "datetime": "2021-06-23 13:52:02",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：海曲泊帕乙醇胺片获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/21173732970356.shtml",
    "datetime": "2021-06-21 17:37:05",
    "code": "600276"
  },
  {
    "title": "里程碑！恒瑞医药卡瑞利珠单抗全球首个一线鼻咽癌适应症获批",
    "href": "http://stock.jrj.com.cn/2021/06/10192832906601.shtml",
    "datetime": "2021-06-10 19:28:01",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用卡瑞利珠单抗新增适应症获批",
    "href": "http://stock.jrj.com.cn/2021/06/10183932906365.shtml",
    "datetime": "2021-06-10 18:39:19",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：抗高血压药阿齐沙坦片获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/10183132906345.shtml",
    "datetime": "2021-06-10 18:31:10",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)大涨近8% 带动创新药板块集体走强",
    "href": "http://stock.jrj.com.cn/2021/06/10103332904069.shtml",
    "datetime": "2021-06-10 10:33:23",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：国家第五批集采对公司业绩会有一定影响",
    "href": "http://stock.jrj.com.cn/2021/06/08144332893166.shtml",
    "datetime": "2021-06-08 14:43:13",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：托伐普坦目前已经取得生产批件",
    "href": "http://stock.jrj.com.cn/2021/06/08144232893165.shtml",
    "datetime": "2021-06-08 14:42:44",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：销售商品、提供劳务与营收差距主要原因是受疫情影响 客户资金紧张 承兑汇票结算比例增加",
    "href": "http://stock.jrj.com.cn/2021/06/08105732892220.shtml",
    "datetime": "2021-06-08 10:57:10",
    "code": "600276"
  },
  {
    "title": "恒瑞医药又一新药将上市分享5亿“蛋糕” 抗肿瘤药收入大增 麻醉业务萎缩",
    "href": "http://stock.jrj.com.cn/2021/06/08081732891731.shtml",
    "datetime": "2021-06-08 08:17:00",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：向药监局药品审评中心递交上市前的沟通交流申请",
    "href": "http://stock.jrj.com.cn/2021/06/04153632874054.shtml",
    "datetime": "2021-06-04 15:36:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：2020年度拟10送2派2元 6月9日股权登记",
    "href": "http://stock.jrj.com.cn/2021/06/03195832870620.shtml",
    "datetime": "2021-06-03 19:58:41",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：福建盛迪医药通过药品GMP符合性检查",
    "href": "http://stock.jrj.com.cn/2021/05/31162732850277.shtml",
    "datetime": "2021-05-31 16:27:01",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用醋酸卡泊芬净国内首家通过一致性评价",
    "href": "http://stock.jrj.com.cn/2021/05/31162332850232.shtml",
    "datetime": "2021-05-31 16:23:48",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：帕立骨化醇注射液通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/05/25154132816528.shtml",
    "datetime": "2021-05-25 15:41:04",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：取得盐酸伊立替康注射液的药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/05/25154032816527.shtml",
    "datetime": "2021-05-25 15:40:39",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)子公司山东盛迪通过药品GMP符合性检查",
    "href": "http://stock.jrj.com.cn/2021/05/25153732816509.shtml",
    "datetime": "2021-05-25 15:37:47",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：银屑病关节炎治疗药获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/20160032787372.shtml",
    "datetime": "2021-05-20 16:00:45",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司SHR-1905注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/18161132776357.shtml",
    "datetime": "2021-05-18 16:11:04",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：公司不存在调节利润的情况",
    "href": "http://stock.jrj.com.cn/2021/05/13153932748384.shtml",
    "datetime": "2021-05-13 15:39:56",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：瑞利迪生物医药有限公司是江苏恒瑞医药有限公司的控股子公司",
    "href": "http://stock.jrj.com.cn/2021/05/13153932748383.shtml",
    "datetime": "2021-05-13 15:39:51",
    "code": "600276"
  },
  {
    "title": "恒瑞医药：公司麻醉业务销售下降一方面受疫情影响手术量下降 另一方面受集采影响部分手术产品销量下降",
    "href": "http://stock.jrj.com.cn/2021/05/13153332748354.shtml",
    "datetime": "2021-05-13 15:33:02",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：子公司注射用卡瑞利珠单抗获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/11180832736444.shtml",
    "datetime": "2021-05-11 18:08:30",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：碘克沙醇注射液通过一致性评价",
    "href": "http://stock.jrj.com.cn/2021/05/11180432736411.shtml",
    "datetime": "2021-05-11 18:04:19",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：HRS8807片用于治疗乳腺癌获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/10170132730269.shtml",
    "datetime": "2021-05-10 17:01:45",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：青岛有沃投资已通过大宗交易减持4950.1万股",
    "href": "http://stock.jrj.com.cn/2021/04/30205832489339.shtml",
    "datetime": "2021-04-30 20:58:46",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：注射用卡瑞利珠单抗获批上市",
    "href": "http://stock.jrj.com.cn/2021/04/30191332488780.shtml",
    "datetime": "2021-04-30 19:13:53",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：奥沙利铂注射液获批上市",
    "href": "http://stock.jrj.com.cn/2021/04/30191032488767.shtml",
    "datetime": "2021-04-30 19:10:28",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：获得SHR1459片的药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2021/04/25164432437989.shtml",
    "datetime": "2021-04-25 16:44:13",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：SHR6390片被纳入拟优先审评品种公示名单",
    "href": "http://stock.jrj.com.cn/2021/04/25164132437970.shtml",
    "datetime": "2021-04-25 16:41:24",
    "code": "600276"
  },
  {
    "title": "安信证券：恒瑞医药2020年业绩稳健增长，卡瑞利珠进一步放量值得期待",
    "href": "http://stock.jrj.com.cn/2021/04/22080632420815.shtml",
    "datetime": "2021-04-22 08:06:53",
    "code": "600276"
  },
  {
    "title": "恒瑞医药2020年净利63.28亿同比增长18.78% 总经理周云曙薪酬480万",
    "href": "http://stock.jrj.com.cn/2021/04/21185932417760.shtml",
    "datetime": "2021-04-21 18:59:50",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：多西他赛注射液通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/04/21170432416792.shtml",
    "datetime": "2021-04-21 17:04:43",
    "code": "600276"
  },
  {
    "title": "恒瑞医药(600276.SH)：盐酸罗哌卡因注射液通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/04/21170332416789.shtml",
    "datetime": "2021-04-21 17:03:01",
    "code": "600276"
  },
  {
    "title": "恒瑞医药召开业绩说明会 董事长周云曙：第五批集采对公司业绩会有一定影响",
    "href": "http://stock.jrj.com.cn/2021/04/21155332416347.shtml",
    "datetime": "2021-04-21 15:53:53",
    "code": "600276"
  }
]